WO2021107414A1 - 죽엽 추출물을 유효성분으로 함유하는 남성 호르몬 의존성 질환의 예방, 개선 또는 치료용 조성물 - Google Patents
죽엽 추출물을 유효성분으로 함유하는 남성 호르몬 의존성 질환의 예방, 개선 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2021107414A1 WO2021107414A1 PCT/KR2020/014701 KR2020014701W WO2021107414A1 WO 2021107414 A1 WO2021107414 A1 WO 2021107414A1 KR 2020014701 W KR2020014701 W KR 2020014701W WO 2021107414 A1 WO2021107414 A1 WO 2021107414A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bamboo leaf
- leaf extract
- dependent diseases
- composition
- prostate
- Prior art date
Links
- 235000017166 Bambusa arundinacea Nutrition 0.000 title claims abstract description 101
- 235000017491 Bambusa tulda Nutrition 0.000 title claims abstract description 101
- 241001330002 Bambuseae Species 0.000 title claims abstract description 101
- 235000015334 Phyllostachys viridis Nutrition 0.000 title claims abstract description 101
- 239000011425 bamboo Substances 0.000 title claims abstract description 101
- 239000000284 extract Substances 0.000 title claims abstract description 87
- 230000001419 dependent effect Effects 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 28
- 201000010099 disease Diseases 0.000 title claims abstract description 26
- 239000004480 active ingredient Substances 0.000 title claims abstract description 16
- 239000003098 androgen Substances 0.000 title abstract description 11
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 31
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 31
- 229940088597 hormone Drugs 0.000 claims description 26
- 239000005556 hormone Substances 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 201000004384 Alopecia Diseases 0.000 claims description 8
- 206010051482 Prostatomegaly Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 201000004240 prostatic hypertrophy Diseases 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 208000028938 Urination disease Diseases 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 abstract description 50
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 34
- 230000014509 gene expression Effects 0.000 abstract description 19
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 abstract description 18
- 101000640851 Homo sapiens 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Proteins 0.000 abstract description 17
- 229960003473 androstanolone Drugs 0.000 abstract description 17
- 229960003604 testosterone Drugs 0.000 abstract description 17
- 102100033875 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Human genes 0.000 abstract description 16
- 101150085994 SRD5A2 gene Proteins 0.000 abstract description 11
- 210000002966 serum Anatomy 0.000 abstract description 10
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 4
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000001339 epidermal cell Anatomy 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 11
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000004209 hair Anatomy 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229960004039 finasteride Drugs 0.000 description 7
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 7
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229960004199 dutasteride Drugs 0.000 description 5
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229940018044 saw palmetto fruit extract Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 244000302661 Phyllostachys pubescens Species 0.000 description 3
- 235000003570 Phyllostachys pubescens Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008556 epithelial cell proliferation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- RZRPTBIGEANTGU-UHFFFAOYSA-N -Androst-4-ene-3,11,17-trione Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)=O)C4C3CCC2=C1 RZRPTBIGEANTGU-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 101100309420 Homo sapiens SRD5A2 gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000003915 Lophatherum gracile Species 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000267040 Sasa borealis Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- RZRPTBIGEANTGU-IRIMSJTPSA-N adrenosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RZRPTBIGEANTGU-IRIMSJTPSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000035252 development of secondary sexual characteristics Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005639 glycero group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 102000043591 human SRD5A2 Human genes 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- -1 olive oil Chemical compound 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 210000001095 prostate stromal cell Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Definitions
- the present invention relates to a composition for preventing, improving or treating male hormone-dependent diseases containing bamboo leaf extract as an active ingredient.
- Androgen is a generic term for hormones that affect the growth and development of the male reproductive system, and is also called male hormone, and refers to all substances that show the action of male hormones.
- As a hormone that acts on the development of secondary sexual characteristics in men it is mainly secreted from the testes of men, and some of it is also secreted from the adrenal cortex and ovaries of women. It is a steroid with 19 carbon atoms and is produced by reduction in cells including testosterone secreted from the testes. These include dehydrotestosterone, which is converted and excreted in urine, androsterone or dehydroepiandrosterone, and adrenosterone secreted from the adrenal cortex.
- BPH benign prostatic hyperplasia
- Bladder storage symptoms such as unbearable urge to urinate, delayed urination (a phenomenon in which urine comes out after steaming when urinating), interrupted urination (a phenomenon in which the flow of urine is interrupted), and the need for force during urination BPH is defined as a complaint of lower urinary tract symptoms, which collectively refers to symptoms indicating bladder discharge disorders such as symptoms.
- Prostate enlargement occurs in the presence of androgens, and anabolic steroids are known to increase prostate capacity and decrease urinary flow, resulting in increased urinary frequency.
- the prostate is an androgen-dependent organ in which testosterone and its extratesticular origin are activated to the more potent dihydrotestosterone (DHT).
- DHT dihydrotestosterone
- the prostate is an important organ for DHT formation, and the systemic effect of the endocrine activity of the prostate is mainly involved in DHT formation and its excretion for circulation.
- the production of DHT increases with age, leading to enlargement and hypertrophy of prostate growth.
- the importance of DHT is confirmed by clinical studies in which 5 ⁇ -reductase inhibitors have been applied to male patients with BPH. In many cases, treatment with 5 ⁇ -reductase inhibitors is known to significantly reduce prostate DHT levels and prostate size.
- Finasteride is widely used for the treatment of androgen-dependent disorders such as male pattern baldness, enlarged prostate (BPH) and prostate cancer. Finasteride is a competitive and specific inhibitor of 5 ⁇ -reductase, which blocks the conversion of testosterone to DHT in the prostate, hair follicles and other androgen-sensitive tissues, resulting in suppression of DHT concentrations in serum and prostate.
- conventionally used drugs such as finasteride and dutasteride have proven to be effective methods of treatment for BPH, their use has been associated with erectile dysfunction, loss of libido, dizziness and the It is strictly limited due to side effects such as upper respiratory tract infection.
- Maengjongjuk is also called Honamjuk, bamboosunjuk, or mojuk, and is characterized by its thick thickness of about 10-20 meters in height.
- the production area is the southern part of the Korean Peninsula, with dark brown spots on the bamboo skin, and it is very hard with little luster. It has the disadvantage of being easy to break due to its low elasticity, so the pupil is often used as it is.
- It contains silicic acid, terpene, and tannin, which has sterilization ability, and generates negative ions to purify blood, increase appetite, stabilize nerves, and recover from fatigue.
- bamboo shoots relieve hangover, relieve stress and insomnia, have diuretic and It is known to help prevent constipation, and it can prevent anticancer action, hypertension, arteriosclerosis, and chronic hepatitis.
- Korean Patent No. 0478021 discloses a method of extracting bamboo leaf extract
- Korean Patent Publication No. 2010-0066743 discloses a composition for improving hair and scalp conditions containing bamboo sap, but the bamboo leaf extract of the present invention is effective
- composition for the prevention, improvement or treatment of male hormone-dependent diseases containing as a component is not disclosed.
- the present invention has been derived from the above needs, and the present invention provides a composition for preventing, improving or treating male hormone-dependent diseases containing bamboo leaf extract as an active ingredient, and the bamboo leaf extract of the present invention contains bamboo leaf extract of different kinds of bamboo Compared to the extract, the expression level of the SRD5A2 gene encoding 5 ⁇ -reductase was significantly reduced, and it was confirmed that there was little cytotoxicity, and it was confirmed that the bamboo leaf extract of the present invention was orally administered in an enlarged prostate animal model. The present invention was completed by confirming that the prostate weight was reduced, the epithelial cell proliferation of the prostate tissue was reduced, and the serum testosterone, dihydrotestosterone, PSA and SRD5A2 contents were reduced.
- the present invention provides a health functional food composition for preventing or improving male hormone-dependent diseases containing bamboo leaf extract as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating male hormone-dependent diseases containing bamboo leaf extract as an active ingredient.
- the present invention provides a cosmetic composition for preventing or improving male hormone-dependent hair loss containing bamboo leaf extract as an active ingredient.
- the present invention has been derived from the above needs, and the present invention relates to a composition for preventing, improving or treating male hormone-dependent diseases containing bamboo leaf extract as an active ingredient, and the bamboo leaf extract of the present invention contains bamboo leaf extract as an active ingredient.
- the bamboo leaf extract of the present invention contains bamboo leaf extract as an active ingredient.
- the extract there is an effect of significantly reducing the expression level of the SRD5A2 gene encoding 5 ⁇ -reductase (5 ⁇ -reductase).
- reduces epithelial cell proliferation in prostate tissue and has the effect of reducing the contents of testosterone, dihydrotestosterone, PSA and SRD5A2 in serum.
- FIG. 1 is a schematic diagram of a luciferase assay system.
- FIG. 2 is a result of a luciferase assay in which SRD5A2 expression changes were analyzed for a damjup hot water extract, damjukyeop ethanol extract, killi hot water extract, bamboo hot water extract and bamboo yup (Maengjongjuk) extract of the present invention.
- C is a vehicle-treated negative control group
- 1 to 3 are 5 ⁇ -reductase inhibitor dutasteride (25 ⁇ M) (1), finasteride (50 ⁇ M) (2) and saw palmetto fruit extract ( SPE, 100 ⁇ g/ml) (3) is a positive control group
- 4 is 30 ⁇ g/ml bamboo leaf (Maengjongjuk, bamboosundae, Phyllostachys pubescens ) 80% ethanol extract treatment group
- 5 is 30 ⁇ g/ml bamboo leaf (Rabunculus, Lophatherum gracile Bronghiart) water extract treatment group
- 6 is 30 ⁇ g / ml 70% ethanol extract treatment group
- 7 is 30 ⁇ g / ml kill hot water extract treatment group
- 8 is 30 ⁇ g / ml Sasa borealis hot water extract treatment group.
- C is a vehicle-treated negative control group
- 1 to 3 are 5 ⁇ -reductase inhibitor dutasteride (25 ⁇ M) (1), finasteride (50 ⁇ M) (2) and saw palmetto fruit extract ( SPE, 100 ⁇ g / ml) (3) treatment group as a positive control group
- 4 is 1 ⁇ g / ml bamboo leaf 80% ethanol extract treatment group
- 5 is 3 ⁇ g / ml bamboo leaf 80% ethanol extract treatment group
- 6 is a group treated with 10 ⁇ g/ml bamboo leaf 80% ethanol extract
- 7 is a group treated with 30 ⁇ g/ml bamboo leaf 80% ethanol extract
- 8 is a group treated with 100 ⁇ g/ml bamboo leaf 80% ethanol extract.
- C is a vehicle-treated negative control group
- 1 to 3 are 5 ⁇ -reductase inhibitor dutasteride (25 ⁇ M) (1), finasteride (50 ⁇ M) (2) and saw palmetto fruit extract ( SPE, 100 ⁇ g / ml) (3) is a positive control group
- 4 is a group treated with 3 ⁇ g / ml bamboo leaf 80% ethanol extract
- 5 is a group treated with 10 ⁇ g / ml bamboo leaf 80% ethanol extract
- 6 is a 30 ⁇ g/ml bamboo leaf 80% ethanol extract treatment group.
- C is a vehicle-treated negative control group
- 1 is a control group treated with 10% DMSO
- 2 to 4 are 5 ⁇ -reductase inhibitor dutasteride (25 ⁇ M) (2), finasteride (50 ⁇ M) ) (3) and saw palmetto fruit extract (SPE, 100 ⁇ g / ml) (4) treated group as a positive control group
- 5 is a group treated with 1 ⁇ g / ml bamboo leaf 80% ethanol extract
- 6 is 3 ⁇ g / ml of bamboo leaf 80% ethanol extract treatment group
- 7 is a bamboo leaf 80% ethanol extract treatment group at 10 ⁇ g/ml
- 8 is a 30 ⁇ g/ml bamboo leaf 80% ethanol extract treatment group
- 9 is 100 ⁇ g/ml bamboo leaf 80% ethanol extract treatment group
- 10 is 300 ⁇ g / ml bamboo leaf 80% ethanol extract treatment group.
- Figure 9 confirms the change in TNF ⁇ content in prostate tissue according to the administration of the bamboo leaf extract of the present invention.
- ### indicates that the TNF ⁇ content in the prostate tissue of the BPH group induced an enlarged prostate compared to the control group was statistically significantly increased, and p ⁇ 0.001.
- **, *** indicates that the TNF ⁇ content in the prostate tissue of the bamboo leaf extract administration group (PPE) of the present invention compared to the prostate enlargement induction group (BPH) was statistically significantly decreased, ** is p ⁇ 0.01, * ** is p ⁇ 0.001.
- the present invention relates to a health functional food composition for preventing or improving male hormone-dependent diseases containing bamboo leaf extract as an active ingredient.
- the bamboo leaf extract may be prepared by a method comprising the following steps, but is not limited thereto:
- step (3) Concentrating the filtered extract of step (2) under reduced pressure and drying to prepare an extract.
- the extraction solvent is preferably selected from water, C 1 to C 4 lower alcohol or a mixture thereof, more preferably ethanol, and still more preferably 80% (v/v) ethanol. It is not limited to this.
- the extraction method may use all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction.
- the extraction solvent is preferably extracted by adding 1 to 20 times the weight of the dried bamboo leaves, and more preferably adding 5 to 15 times.
- the extraction temperature is preferably 20 ⁇ 90 °C, but is not limited thereto.
- the extraction time is preferably 0.5 to 10 hours, more preferably 3 to 7 hours, and most preferably 3 hours or 5 hours, but is not limited thereto.
- the vacuum concentration in step (3) is preferably using a vacuum vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto.
- the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying, freeze drying or microwave drying, but is not limited thereto.
- the bamboo leaf is preferably a leaf of Maengjongjuk, but is not limited thereto.
- the male hormone-dependent disease is preferably any one selected from alopecia, acne, seborrheic dermatitis, prostatitis, prostatic hyperplasia and urination disorder caused by an enlarged prostate, but is not limited thereto.
- the health functional food composition for preventing or improving male hormone-dependent diseases comprising the bamboo leaf extract as an active ingredient is prepared in any one formulation selected from beverages, pills, tablets, capsules and powders, or food It can be prepared by adding it as a component of , and can be appropriately prepared according to a conventional method.
- Examples of foods to which the bamboo leaf extract of the present invention can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, It may be in any one form selected from tea, drinks, alcoholic beverages, and vitamin complexes, and includes all health functional foods in a conventional sense.
- the health functional food includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavorants, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alkynic acid and its salts, organic acids, protective colloidal thickeners , a pH adjuster, a stabilizer, a preservative, glycerin, alcohol, a carbonation agent used in carbonated beverages, and the like. In addition, it may contain the pulp for the production of natural fruit juices and vegetable beverages. These components may be used independently or in combination.
- the health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients.
- the natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- sweetener natural sweeteners such as taumatine and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used.
- the present invention relates to a pharmaceutical composition for preventing or treating male hormone-dependent diseases containing bamboo leaf extract as an active ingredient.
- the male hormone-dependent disease is preferably any one selected from alopecia, acne, seborrheic dermatitis, prostatitis, prostatic hyperplasia and urination disorder caused by an enlarged prostate, but is not limited thereto.
- a pharmaceutically acceptable carrier, excipient or diluent may be included.
- the pharmaceutical composition of the present invention may be prepared in any one formulation selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups and aerosols, but is not limited thereto.
- the pharmaceutical composition of the present invention may be administered orally or parenterally, and when administered parenterally, it is preferable to select an external skin or intraperitoneal, rectal, intravenous, muscle, subcutaneous, intrauterine dural or intracerebrovascular injection method, and most Preferably, it is used for external use on the skin.
- the pharmaceutical composition of the present invention may be prepared using a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, and a surfactant.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in one or more compounds, for example, starch, calcium carbonate, sucrose or lactose ( lactose), gelatin, etc.
- lubricants such as magnesium stearate and talc are also used.
- Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories.
- Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin, glycero gelatin, etc. may be used.
- composition according to the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type, severity, and drug activity of the patient. , sensitivity to drugs, administration time, administration route and excretion rate, duration of treatment, factors including concurrent drugs, and other factors well known in the medical field.
- the composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple. In consideration of all of the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.
- the dosage of the composition of the present invention can be used in various ranges depending on the weight, age, sex, health status, diet, administration time, administration method, excretion rate and severity of the disease of the patient.
- the present invention relates to a cosmetic composition for preventing or improving male hormone-dependent hair loss containing bamboo leaf extract as an active ingredient.
- the cosmetic composition according to the present invention may be a hair cleanser composition, and is formulated as hair shampoo, hair conditioner, hair conditioner, hair treatment, hair tonic, scalp treatment, hair lotion, hair cream, hair nourishing lotion or general ointment.
- BPH-1 Human benign prostatic hyperplasia epithelial cells (BPH-1) were cultured in RPMI1640 containing 20% FBS and 1% antibiotics in a 5% CO 2 incubator at 37°C. It was subcultured every 48 hours to maintain adequacy in the range of 70-90%. One day before the experiment, the cells were cultured for 24 hours after dispensing for stabilization.
- Maengjongjuk (bamboosundae, Phyllostachys pubescens ) leaves 1 kg were immersed in 15 liters of 80% (v/v) ethanol for 1 week, and then extracted and filtered at 80° C. for 5 hours. Then, the extract solution was concentrated under reduced pressure to obtain a bamboo leaf extract. This was used in Examples 4 to 6.
- a luciferase assay system was constructed ( FIG. 1 ). After cloning the promoter (about 1.6 kb) of the human SRD5A2 gene into a firefly luciferase reporter, transient transfection into BPH-1 cells, and then, by measuring the luminescence degree of firefly luciferase, lucifera A luciferase assay system was constructed to analyze the enzyme reporter activity.
- Example 3 In order to select a candidate group capable of reducing the expression level of the SRD5A2 gene in the herbal medicine library, the luciferase assay constructed in Example 3 was performed.
- the cell viability was confirmed by treating the cells with the bamboo leaf extract in a concentration-dependent manner.
- BPH-1 cells were treated at a density of 2 to 3 ⁇ 10 4 cells/well in a 48-well plate and cultured for 24 hours, followed by treatment with 1-300 ⁇ g/ml bamboo leaf extract for 24 hours. After the MTS reagent was added to the reaction cells, the cells were further cultured for 4 hours, and the absorbance was measured using a microplate reader at a wavelength of 490 nm to measure the cell viability.
- the cell viability of the experimental group treated with the bamboo leaf extract at 1-300 ⁇ g/ml was at a level similar to that of the control group, and it was determined that the bamboo leaf extract had no cytotoxicity.
- 7-week-old male rats (280 ⁇ 10 g) were purchased from Daehan Biolink and tested. Experimental animals were acclimatized for 1 week by supplying sufficient solid feed (antibiotic-free, Samyang Feed Co.) and water until the day of the experiment, maintaining an environment of 22 ⁇ 2°C temperature, 55 ⁇ 15% humidity, and a 12-hour light-dark cycle. It was used for later experiments. In order to review the ethical and scientific feasibility of animal experiments and to efficiently manage them, it was carried out with the approval of the Animal Experimental Ethics Committee [approval number: DJUARB2020-017].
- the rats were anesthetized, the scrotal skin of the rats was incised, the vas deferens, blood vessels, and nerve tissue in the upper part of the testicles were tied with sutures, and the testes and epididymis were resected. went through a period of recovery.
- Prostate hypertrophy was induced by subcutaneous injection of testosterone propionate (testosterone, 5 mg/kg) once a day for 4 weeks in all experimental animals except the control group from the 2nd day after orchiectomy. 50, 100 and 200 mg/kg of bamboo leaf extract was orally administered once a day for 4 weeks.
- Testosterone, DHT, PSA and SRD5A2 contents in serum of each group were analyzed by ELISA using Mybiosource (USA) ELISA Kit.
- the content of testosterone, DHT, PSA and SRD5A2 in the BPH group compared to the control group (CON) increased statistically significantly
- testosterone, DHT, PSA and SRD5A2 in the serum of the bamboo leaf extract-administered group (PPE) of the present invention compared to the BPH group.
- the content of was decreased statistically significantly (Fig. 6).
- the prostate weight of the BPH group induced by prostate enlargement compared to the control group increased statistically significantly
- the bamboo leaf extract administration group of the present invention compared to the prostate enlargement induction group (BPH) ( It was confirmed that the prostate weight of PPE) decreased statistically significantly ( FIG. 7 ).
- Prostate tissue was fixed with 4% paraformaldehyde, embedded in paraffin, and sections were obtained, followed by H&E staining, and histological changes of epithelial cells and stroma of the prostate were confirmed under an optical microscope.
- one layer of low columnar epithelial cells constitutes secretory luminal cells, and the cavity is filled with a light eosinophilic substance, but testosterone In the BPH group, which induced prostatic hypertrophy, hyperproliferative findings with increased prostate epithelial thickness were observed, and stromal fibrovascular proliferation was confirmed.
- the bamboo leaf extract according to the present invention suppressed the proliferation of epithelial cells of the prostate tissue. It was judged to be effective in prostatic hyperplasia by reducing it.
- the primary antibody was diluted in a blocking solution and reacted at room temperature for 4 hours, washed 3 times for 10 minutes with PBS-T, and the secondary antibody was diluted in blocking buffer and reacted for 2 hours at room temperature under conditions of blocking light. After washing, it was washed once with PBS-T for 10 minutes.
- Hoechst 33258 was reacted with PBS-T solution, washed with PBS-T for 10 minutes, and then a cover glass (22 ⁇ 50 mm, Marienfeld-superior, Germany) was slided using GEL/MOUNT (Biomeda, USA). It was covered and dried in the dark at room temperature.
- the primary antibody used for staining was TNF ⁇ (Abcam, UK), and the secondary antibody was a fluoroserine goat anti-mouse IgG antibody (H+L) (Invitrogen, USA), rhodamine goat anti-rabbit. Antibody (Invitrogen, USA) was used. Images were acquired from the stained slides using a fluorescence microscope (Nikon, Japan) and ACT-1 software.
- the expression of TNF- ⁇ in the prostate tissue of the testosterone administration group (BPH) was significantly increased compared to the normal group (Con), but the prostate of the bamboo salt extract administration group (PPE) of the present invention
- the expression of TNF- ⁇ in the tissue was statistically significantly decreased than in the testosterone-administered group (BPH).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (8)
- 죽엽 추출물을 유효성분으로 함유하는 남성 호르몬 의존성 질환의 예방 또는 개선용 건강기능식품 조성물.
- 제1항에 있어서, 상기 죽엽 추출물의 추출용매는 물, C 1~C 4의 저급 알코올 또는 이들의 혼합물인 것을 특징으로 하는 남성 호르몬 의존성 질환의 예방 또는 개선용 건강기능식품 조성물.
- 제1항에 있어서, 상기 죽엽은 맹종죽의 잎인 것을 특징으로 하는 남성 호르몬 의존성 질환의 예방 또는 개선용 건강기능식품 조성물.
- 제1항에 있어서, 상기 남성 호르몬 의존성 질환은 탈모증, 여드름, 지루성 피부염, 전립선염, 전립선 비대증 및 전립선 비대증에 의한 배뇨장애 중에서 선택된 어느 하나인 것을 특징으로 하는 남성 호르몬 의존성 질환의 예방 또는 개선용 건강기능식품 조성물.
- 제1항에 있어서, 죽엽 추출물은 음료, 환, 정제(tablet), 캡슐제(capsule) 및 산제 중에서 선택된 어느 하나의 제형으로 제조되는 것을 특징으로 하는 남성 호르몬 의존성 질환의 예방 또는 개선용 건강기능식품 조성물.
- 죽엽 추출물을 유효성분으로 함유하는 남성 호르몬 의존성 질환의 예방 또는 치료용 약학 조성물.
- 제6항에 있어서, 상기 죽엽 추출물 이외에 추가로 담체, 부형제 또는 희석제를 포함하는 것을 특징으로 하는 남성 호르몬 의존성 질환의 예방 또는 치료용 약학 조성물.
- 죽엽 추출물을 유효성분으로 함유하는 남성 호르몬 의존성 탈모의 예방 또는 개선용 화장료 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/038,537 US20240016878A1 (en) | 2019-11-29 | 2020-10-27 | Composition for preventing, ameliorating or treating androgen-dependent disorder comprising phyllostachys pubescens extract as effective component |
CA3200081A CA3200081A1 (en) | 2019-11-29 | 2020-10-27 | Composition for preventing, ameliorating or treating androgen-dependent disorder comprising phyllostachys pubescens extract as effective component |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190156718 | 2019-11-29 | ||
KR10-2019-0156718 | 2019-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021107414A1 true WO2021107414A1 (ko) | 2021-06-03 |
Family
ID=76128678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/014701 WO2021107414A1 (ko) | 2019-11-29 | 2020-10-27 | 죽엽 추출물을 유효성분으로 함유하는 남성 호르몬 의존성 질환의 예방, 개선 또는 치료용 조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240016878A1 (ko) |
KR (1) | KR102277092B1 (ko) |
CA (1) | CA3200081A1 (ko) |
WO (1) | WO2021107414A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102563878B1 (ko) * | 2021-09-06 | 2023-08-04 | 충남대학교산학협력단 | 대계 추출물을 유효성분으로 포함하는 전립선 질환의 예방, 개선 또는 치료용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040006704A (ko) * | 2002-07-13 | 2004-01-24 | 김우영 | 탈모방지 및 발모에 효과적인 건강보조식품 및 이의제조방법 |
KR20050117797A (ko) * | 2004-06-11 | 2005-12-15 | 주식회사 유니젠 | 대나무 또는 대나무 추출물을 포함하는 안드로젠 효능성조성물 |
JP2007505151A (ja) * | 2003-05-25 | 2007-03-08 | 杭州浙大力夫生物科技有限公司 | 竹葉フラボンの前立腺疾病の予防・治療薬物及び保健食品における応用 |
KR20120041514A (ko) * | 2010-10-21 | 2012-05-02 | 김상섭 | 한방 생약재 추출물을 포함하는 탈모방지 및 발모용 세정제 조성물 및 이의 제조방법 |
KR20130075511A (ko) * | 2011-12-27 | 2013-07-05 | (주) 젠셀 | 천연물 복합 발효 추출물을 유효성분으로 하는 발모제 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090090758A (ko) * | 2008-02-22 | 2009-08-26 | 최효근 | 발모 촉진 또는 탈모 방지용 조성물 |
KR20100083939A (ko) * | 2009-01-15 | 2010-07-23 | 김현정 | 홍삼 및 홍삼 제조방법 |
KR20140017732A (ko) * | 2012-07-31 | 2014-02-12 | 한일인삼산업 주식회사 | 체내흡수율이 증강된 발효홍삼 농축액 제조방법 |
KR101690779B1 (ko) * | 2015-01-22 | 2016-12-29 | 재단법인 진안홍삼연구소 | 홍삼농축분말 및 복분자완숙과추출물을 함유하는 발효물의 제조방법 및 상기 방법으로 제조된 발효물 |
-
2020
- 2020-10-27 US US18/038,537 patent/US20240016878A1/en active Pending
- 2020-10-27 WO PCT/KR2020/014701 patent/WO2021107414A1/ko active Application Filing
- 2020-10-27 KR KR1020200140104A patent/KR102277092B1/ko active IP Right Grant
- 2020-10-27 CA CA3200081A patent/CA3200081A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040006704A (ko) * | 2002-07-13 | 2004-01-24 | 김우영 | 탈모방지 및 발모에 효과적인 건강보조식품 및 이의제조방법 |
JP2007505151A (ja) * | 2003-05-25 | 2007-03-08 | 杭州浙大力夫生物科技有限公司 | 竹葉フラボンの前立腺疾病の予防・治療薬物及び保健食品における応用 |
KR20050117797A (ko) * | 2004-06-11 | 2005-12-15 | 주식회사 유니젠 | 대나무 또는 대나무 추출물을 포함하는 안드로젠 효능성조성물 |
KR20120041514A (ko) * | 2010-10-21 | 2012-05-02 | 김상섭 | 한방 생약재 추출물을 포함하는 탈모방지 및 발모용 세정제 조성물 및 이의 제조방법 |
KR20130075511A (ko) * | 2011-12-27 | 2013-07-05 | (주) 젠셀 | 천연물 복합 발효 추출물을 유효성분으로 하는 발모제 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20210067878A (ko) | 2021-06-08 |
CA3200081A1 (en) | 2021-06-03 |
KR102277092B1 (ko) | 2021-07-15 |
US20240016878A1 (en) | 2024-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100105766A1 (en) | Composition for inhibition or prevention of bone density reduction | |
KR102592438B1 (ko) | 안드로겐 시그널링 관련 인자 ar 및 5ar2 발현 저해용 시약 조성물 | |
Ong et al. | Paeoniflorin extract reverses dexamethasone-induced testosterone over-secretion through downregulation of cytochrome P450 17A1 expression in primary murine theca cells | |
WO2021107414A1 (ko) | 죽엽 추출물을 유효성분으로 함유하는 남성 호르몬 의존성 질환의 예방, 개선 또는 치료용 조성물 | |
KR101485705B1 (ko) | 향부자 추출물로부터 분리된 세스퀴테르페노이드계 화합물을 함유하는, 갱년기 질환의 예방 또는 치료용 조성물 | |
JP7117030B2 (ja) | ゴカヒ、ロコン、及びアカマツ抽出物を有効成分として含む前立腺疾患の予防、治療、又は改善用組成物 | |
KR102583293B1 (ko) | 단삼(Salvia miltiorrhiza Bunge) 추출물을 유효성분으로 포함하는 전립선비대증 또는 탈모증의 치료 또는 예방용 조성물 | |
KR101863731B1 (ko) | 큰황새냉이 추출물을 유효성분으로 함유하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
WO2021086120A1 (ko) | 단삼(Salvia miltiorrhiza Bunge) 추출물을 유효성분으로 포함하는 전립선비대증 또는 탈모증의 치료 또는 예방용 조성물 | |
KR101876201B1 (ko) | 자근 추출물을 유효성분으로 포함하는 안드로겐 수용체 관련 질환의 예방, 개선 또는 치료용 조성물 | |
KR20220029479A (ko) | 순비기나무 추출물을 포함하는 여성 갱년기 증상 예방 또는 치료용 약학적 조성물 | |
KR101451872B1 (ko) | 알파-스피나스테롤을 유효성분으로 포함하는 안드로겐-관련 질환, 질병 또는 상태 예방 또는 치료용 약제학적 조성물 | |
KR101895850B1 (ko) | 벌씀바귀 추출물을 유효성분으로 함유하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
JP7518580B2 (ja) | ウチワノキ抽出物を有効成分として含むアンドロゲン受容体関連疾患治療用薬学的組成物 | |
KR102154077B1 (ko) | 구자 추출물을 유효성분으로 포함하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
KR102168459B1 (ko) | 전립선 문제를 해결하기 위한 치료제로서 쿠르쿠마 망가 발 에 지프 추출물 | |
KR102146567B1 (ko) | 패랭이꽃 식물 추출물을 유효성분으로 포함하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
KR102536101B1 (ko) | 선학초 추출물을 유효성분으로 포함하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
KR102376510B1 (ko) | 산달래 추출물을 유효성분으로 포함하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
KR101918023B1 (ko) | 미국개기장 추출물을 유효성분으로 함유하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
KR101923170B1 (ko) | 나도개피 추출물을 유효성분으로 함유하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
KR101896049B1 (ko) | 큰피막이 추출물을 유효성분으로 함유하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
KR20130133477A (ko) | 상황버섯 추출물의 전립선 비대증 개선, 여드름 개선, 발모 촉진 용도 | |
KR102224701B1 (ko) | 목통 추출물을 유효성분으로 포함하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
KR20240078103A (ko) | 대복피 추출물을 유효성분으로 함유하는 만성 췌장염의 예방, 개선 및 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20892794 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20892794 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3200081 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18038537 Country of ref document: US |